Related Experiment Videos
Mesulergine in early Parkinson's disease: a double blind controlled trial
Abstract:
The efficacy and tolerance of treatment with an 8-alpha-amino-ergoline derivative CU32-o85, Mesulergine, were compared with levodopa/benserazide (Madopar) in a 3 month double-blind controlled trial in 31 patients with Parkinson's disease, not previously treated with levodopa. The two treatments were equally well tolerated, and neither dyskinesias nor dose-related fluctuations developed. In 90% of the patients treated with Mesulergine, Parkinsonian symptoms improved, and at the dose given the overall therapeutical response was two-thirds that of levodopa. During further 9 months of open study the beneficial effect was maintained equally well in both groups. Compared with other dopamine agonists Mesulergine has a considerable antiparkinsonian effect. Unfortunately, further clinical evaluation of the compound recently has been stopped owing to sex and species specific histological alterations in rats. It is suggested that Mesulergine derivatives might well be of value in future treatment of early Parkinson's disease and of late incompensated stages.
Insights
Mesulergine, an 8-alpha-amino-ergoline derivative, showed comparable tolerance to levodopa/benserazide for Parkinson's disease treatment. While effective, its development was halted due to rat-specific histological changes.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Current treatments like levodopa/benserazide have limitations.
- Novel therapeutic agents are needed for early and advanced PD stages.
Purpose of the Study:
- To compare the efficacy and tolerance of Mesulergine (CU32-o85) with levodopa/benserazide in early-stage Parkinson's disease.
- To evaluate the long-term effects of Mesulergine in Parkinson's disease patients.
Main Methods:
- A 3-month double-blind, controlled trial involving 31 levodopa-naïve Parkinson's disease patients.
- Comparison of Mesulergine versus levodopa/benserazide (Madopar).
- Followed by a 9-month open-label study.
Main Results:
- Both treatments were equally well tolerated, with no dyskinesias or dose-related fluctuations observed.
- Mesulergine improved Parkinsonian symptoms in 90% of patients, with a therapeutic response two-thirds that of levodopa.
- Beneficial effects were maintained equally in both groups during the open-label phase.
Conclusions:
- Mesulergine demonstrates significant antiparkinsonian effects, comparable in tolerance to levodopa/benserazide.
- Despite promising efficacy, further clinical development was discontinued due to observed histological alterations in rats.
- Mesulergine derivatives may hold potential for future Parkinson's disease treatment, particularly in early or decompensated stages.